OM:MCOV BHealthcare
Medicover (OM:MCOV B) Valuation in Focus After DART Study Highlights Early Lung Cancer Detection Breakthrough
Medicover (OM:MCOV B) revealed new findings from its DART clinical study, highlighting that its ctDNA-based MRD assay can predict disease progression in stage III non-small cell lung cancer months ahead of standard imaging. These results, recently presented at a major oncology congress, could shape how investors view the company's long-term prospects.
See our latest analysis for Medicover.
The spotlight from Medicover’s DART study results comes as the company’s stock continues to attract...